The sustained in-site release of SN38 and aOX40 activate STING pathway, synergistically facilitate dendritic cell (DC) activation, modulates immunosuppressive TME induced by surgery and residual tumor, and initiate persistent and durable tumoricidal immunity within the surgical resection bed. This evidence concerns the gene STING1 and neoplasm.